menu
    • menu
    [{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"JBI-589","moa":"PAD4","graph1":"Immunology","graph2":"Preclinical","graph3":"Jubilant Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jubilant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Jubilant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"JBI-778","moa":"PRMT5","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jubilant Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jubilant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Jubilant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"JBI-802","moa":"LSD1\/HDAC6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jubilant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jubilant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jubilant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"JBI-802","moa":"LSD1\/HDAC6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jubilant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jubilant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jubilant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"JBI-2174","moa":"PD-L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jubilant Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jubilant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Jubilant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"JBI-778","moa":"PRMT5","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jubilant Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jubilant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Jubilant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"JBI-802","moa":"LSD1\/HDAC6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jubilant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jubilant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jubilant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"JBI-802","moa":"LSD1\/HDAC6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jubilant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jubilant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jubilant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"JBI-802","moa":"LSD1\/HDAC6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jubilant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jubilant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jubilant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"JBI-1044","moa":"PAD4","graph1":"Oncology","graph2":"Preclinical","graph3":"Jubilant Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jubilant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Jubilant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"JBI-802","moa":"LSD1\/HDAC6","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Jubilant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jubilant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jubilant Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Jubilant Therapeutics

    Menu

    Jubilant Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Jubilant Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Jubilant Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JBI-802

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Jubilant Starts Trials for JBI-802 And JBI-778 in Global Studies

                            Details : JBI-802 is a first-in-class, orally administered CoREST Inhibitor, small molecule drug candidate, which is currently being evaluated for the treatment of solid tumors.

                            Product Name : JBI-802

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 25, 2024

                            Lead Product(s) : JBI-802

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Jubilant Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Jubilant Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JBI-802

                            Therapeutic Area : Hematology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            JBI-802 Phase I Data Suggests Potential in Immunotherapy-Resistant Tumors

                            Details : JBI-802 is a first-in-class CoREST inhibitor with dual action on LSD1 and HDAC6, undergoing phase 1/2 trials for essential thrombocythemia and related neoplasms.

                            Product Name : JBI-802

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 01, 2024

                            Lead Product(s) : JBI-802

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Jubilant Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Jubilant Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JBI-802

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Jubilant Therapeutics Inc. Receives Orphan Drug Designation for Jbi-802 for Acute Myeloid Leukemia (AML) and S...

                            Details : JBI-802 is an oral, potent and selective dual inhibitor of two epigenetic targets of the CoREST complex: LSD1 and HDAC6. It targets stem cell modulation by inhibiting LSD1 and modulates immune suppression with isoform selective HDAC6 inhibition.

                            Product Name : JBI-802

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 01, 2023

                            Lead Product(s) : JBI-802

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Jubilant Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Jubilant Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JBI-589

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Jubilant Therapeutics Inc.'s Selective, Orally Administered PAD4 Inhibitor Demonstrates Activity in Rheumatoid...

                            Details : JBI-589 is a PAD4 inhibitor which inhibits NET formation, in vitro resulting in reduced measures of RA and inflammation including joint erosion, RA clinical score and inflammatory markers.

                            Product Name : JBI-589

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 13, 2023

                            Lead Product(s) : JBI-589

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Jubilant Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Jubilant Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JBI-778

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Jubilant Therapeutics Inc. Receives Orphan Drug Designation For The PRMT5 Inhibitor - JBI-778 For the Treatmen...

                            Details : JBI-778 is a potent and selective brain penetrant inhibitor of PRMT5, which is overexpressed in many cancers. JBI-778 is in development for the treatment of advance cancers with specific genetic mutations, and patients with high-grade glioma.

                            Product Name : JBI-778

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 13, 2023

                            Lead Product(s) : JBI-778

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Jubilant Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Jubilant Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JBI-1044

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Jubilant Therapeutics Inc. to Present Data on Isoform Selective PAD4 inhibitors in the Treatment of Cancer at ...

                            Details : JBI-1044, first-in-class PAD4 inhibitors with potential to be a next-generation treatment for an autoimmune disease with broad disease application including NETosis mediated tumor metastasis.

                            Product Name : JBI-1044

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 03, 2022

                            Lead Product(s) : JBI-1044

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Jubilant Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Jubilant Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JBI-802

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Jubilant Therapeutics Announces FDA Clearance of IND for JBI-802, a Novel Dual LSD1 and HDAC6 Inhibitor, for t...

                            Details : JBI-802, a novel dual LSD1 and HDAC6 Inhibitor received FDA Clearance of IND, on the basis of preclinical data that has demonstrated synergistic anti-tumor activity, and a favorable safety profile with no significant safety concerns or accumulation.

                            Product Name : JBI-802

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 01, 2022

                            Lead Product(s) : JBI-802

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Jubilant Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Jubilant Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JBI-802

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Jubilant Therapeutics Inc. Doses First Patient in Phase I/II Trial Evaluating JBI-802, dual inhibitor of LSD1 ...

                            Details : JBI-802 is a first-in-class, small-molecule, orally administered selective dual inhibitor of two epigenetic targets of the CoREST complex: LSD1 and HDAC6, that has demonstrated synergistic anti-tumor activity in animal models.

                            Product Name : JBI-802

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 26, 2022

                            Lead Product(s) : JBI-802

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Jubilant Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Jubilant Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JBI-778

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Jubilant Therapeutics Inc. Announces US FDA Clearance of IND for JBI-778, an Oral, Brain Penetrant and Selecti...

                            Details : JBI-778, an oral, brain penetrant and selective protein arginine methyl transferase 5 (PRMT5) inhibitor, for the treatment of solid tumors with brain metastases and primary brain tumors including high-grade glioma.

                            Product Name : JBI-778

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 08, 2022

                            Lead Product(s) : JBI-778

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Jubilant Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Jubilant Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JBI-2174

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Jubilant Therapeutics Inc. Reports Development of Orally Available and Brain Penetrant Small Molecule Inhibito...

                            Details : JBI-2174, anti-PD-L1 candidate demonstrated strong affinity for PD-L1 with an IC50 of approximately 1 nM. In selectivity assays for immune-oncology targets, JBI-2174 was highly selective for PD-L1 also inhibited PD-L1/PD-1 mediated signaling essential fo...

                            Product Name : JBI-2174

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 06, 2022

                            Lead Product(s) : JBI-2174

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth